BNP Paribas Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

BNP Paribas Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-345,791	Closed	-$9.28M	–	957
2022 Q1	$9.28M	Sell	345,791 -29,119	-8%	-$979K	0.03%	424
2021 Q4	$17.9M	Buy	374,910 +7,829	+2%	+$350K	0.06%	340
2021 Q3	$24.4M	Buy	367,081 +64,503	+21%	+$4.6M	0.09%	255
2021 Q2	$23.6M	Buy	302,578 +79,647	+36%	+$5.89M	0.08%	277
2021 Q1	$21.1M	Sell	222,931 -45,160	-17%	-$5.37M	0.09%	271
2020 Q4	$32.7M	Sell	268,091 -5,480	-2%	-$600K	0.15%	171
2020 Q3	$23.9M	Buy	273,571 +53,987	+25%	+$3.76M	0.14%	186
2020 Q2	$14.2M	Buy	+219,584	New	+$12.7M	0.1%	241

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BNP Paribas Asset Management's TPTX Position: Q2 2022 in Review

BNP Paribas Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 345,791 shares — an estimated $9.28M sold.

BNP Paribas Asset Management first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $32.7M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

BNP Paribas Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
BNP Paribas Asset Management sold 345,791 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $9.28M.
BNP Paribas Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
BNP Paribas Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $32.7M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on BNP Paribas Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.